PanTher Therapeutics is a clinical-stage oncology company revolutionizing cancer care by harnessing sustained treatments engineered for localized applications. We are Attacking Cancer at The Source™ by providing therapeutics on target. PanTher mission is to redefine cancer treatment with therapeutics designed to act precisely at the tumor site for enhanced clinical outcomes and minimal side effects. We empower oncologists to better treat cancer patients by unlocking a drug’s full potential through direct, sustained treatment at the tumor site. Our innovative Sagittari™ platform enables to engineer optimized therapeutic solutions to address the specific challenges dictated by tumor type, location, and ideal therapeutic regimen. PanTher lead candidate, PTM-101, is a minimally invasive, implantable treatment for pancreatic cancer currently being evaluated in a Phase 1 clinical trial as first line therapy for localized non-metastatic pancreatic cancers.
Developing a method of therapeutic hypothermia or medical protective cooling for hospital cardiac arrest and minimally invasive surgeries to prevent warm ischemia and surgical trauma.
Treatment of addictions to smoking, alcohol, and diet through behavioral monitoring via wearable device and app platform.
Khanicheh brings 15 years of experience in the medical device innovation and research space. After receiving her PhD in Mechanical and Biomedical Engineering from Northeastern she worked throughout Massachusetts, including 15 issued and pending patents. EnVision Endoscopy is working on a suturing adjunct that can be used with any endoscope. By decreasing the number of steps and procedure time, the cost is decreased and this allows for access to a greater number of gastroenterologists and surgeons.
Yen is a recent PhD graduate from Tufts University. During her tenure there, she worked on developing a bacteriophage product to combat household transmission of cholera. PhagePro was founded to not only continue this work but also develop phage products for emerging markets. Their initial target is cholera and by offering an oral product that offers immediate protection, families of patients infected with cholera will be able to take care of their loved ones without fear while also curbing outbreaks in the community.
Developer of a rapid hand disinfection system to reduce healthcare associated infections.
This company has closed.
Ripka brings 23 years of drug discovery experience and expertise to her role at Lucy Therapeutics. She has over 30 issued chemical patents and has worked in drug discovery from screening through IND. Ripka has also led international research conferences and served as a scientific advisor to multiple biotechs. She is applying this experience to LucyTx’s goal of generating a new mitochondrial platform for the discovery of neurological therapies, first focusing on Rett Syndrome and Parkinson’s Disease. LucyTx targets mitochondrial nexus points, which can address both the genetic and environmental factors in these diseases.
This company has closed.
New Equilibrium Bioscience’s mission is to discover new medicines for life-threatening diseases with a focus on extending the health span of patients. We leverage our computational-experimental platform to discover lead drug candidates that regulate intrinsically disordered proteins implicated in cancers and neurodegenerative disorders.
This company has closed.
Developing a new generation of fluid-guiding, and biocontamination-resistant medical conduits (e.g. tubes and shunts) that can be customized to address the need for more efficacious drug delivery or drainage of biological fluids in different parts of the human body. PionEar’s first product is a bioinspired tympanostomy tube (also known as an ear tube) that allows antibiotic drops to penetrate the middle ear more efficiently than existing tubes for a more effective resolution of infection and reduces the risk of unnecessary revision surgeries and complications.
This company has closed.
Aiming to transform the field of surgical and topical adhesive materials with a family of proprietary internal, external and reversible adhesive materials that reacts in a graded manner with each tissue as a function of type and state to provide adequate adhesion while maintaining biocompatibility
Developer of a precision medicine platform designed to provide the right drug to the right patient.
Phiex Technologies enables medical device makers to sterilize critical devices in-line with self-sterilizing materials, providing a safe, cost/time-savings alternative to the cancer-causing status quo.
Robigo is leveraging cutting edge biotechnology and data science to develop a new class of precision microbials to protect crops, fight disease, and improve overall yields while creating a more sustainable future for agriculture.
Guardian Bio is developing a first-in-class therapy leveraging a newly defined type of dendritic cell designed to launch a personalized anti-tumor immune response in cancer patients.
This company has been paused.
Promakhos Therapeutics is developing curative therapies that restore the function of the immune system, allowing the body to control inflammation and heal.
Lightfinder is developing a high-resolution 3D tissue imager on-a-chip that will enable a more accurate, efficient, and less costly tissue diagnostic pathology process.
DoriNano is developing first-in-class transformative nanoparticle-based combination immunotherapies for cancer patients.
General Prognostics (GPx) is addressing heart failure management with a non-invasive, cost-effective technology that uses smartwatch data and proprietary algorithms to deliver continuous NT-proBNP insights, reducing hospital readmissions and costs while positioning itself as a B2B subscription service for cardiologists and HF centers.
Cellens is pioneering an AI-driven mechanobiology platform, BioFeel™, to bring clarity and comfort to cancer monitoring.
EntoCellular is developing high-quality animal protein through innovative insect cell cultivation, offering a sustainable, cruelty-free alternative to farmed animal protein for pets.
Lybra Bio is developing next-generation platforms aimed at treating autoimmune skin disorders with precision and long-lasting results.
RedPoint Oncology is building a new payload class for targeted cancer therapies, designed to eliminate therapy-resistant tumors where current treatments fail.
